Jan A. Burger

37.6k total citations · 9 hit papers
431 papers, 20.9k citations indexed

About

Jan A. Burger is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Jan A. Burger has authored 431 papers receiving a total of 20.9k indexed citations (citations by other indexed papers that have themselves been cited), including 358 papers in Genetics, 180 papers in Pathology and Forensic Medicine and 162 papers in Hematology. Recurrent topics in Jan A. Burger's work include Chronic Lymphocytic Leukemia Research (342 papers), Lymphoma Diagnosis and Treatment (179 papers) and Chronic Myeloid Leukemia Treatments (114 papers). Jan A. Burger is often cited by papers focused on Chronic Lymphocytic Leukemia Research (342 papers), Lymphoma Diagnosis and Treatment (179 papers) and Chronic Myeloid Leukemia Treatments (114 papers). Jan A. Burger collaborates with scholars based in United States, Italy and Germany. Jan A. Burger's co-authors include Thomas J. Kipps, William G. Wierda, Michael J. Keating, Meike Burger, Hagop M. Kantarjian, Susan O’Brien, Alessandra Ferrajoli, Amnon Peled, Zeev Estrov and Nicholas Chiorazzi and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Jan A. Burger

415 papers receiving 20.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

2005 955 citations Jan A. Burger, Thomas J. Kipps Blood profile →
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1

2000 606 citations Jan A. Burger, Thomas J. Kipps et al. Blood profile →
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

2011 499 citations William G. Wierda, Michael J. Keating et al. Blood profile →
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

2015 484 citations John C. Byrd, Richard R. Furman et al. Blood profile →
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

2019 307 citations Susan O’Brien, Jacqueline C. Barrientos et al. American Journal of Hematology profile →
Targeting B cell receptor signalling in cancer: preclinical and clinical advances

2018 296 citations Jan A. Burger et al. profile →
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

2022 146 citations Paul M. Barr, Jan A. Burger et al. profile →

Peers

Countries citing papers authored by Jan A. Burger

Since Specialization

Citations

This map shows the geographic impact of Jan A. Burger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan A. Burger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan A. Burger more than expected).

Fields of papers citing papers by Jan A. Burger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan A. Burger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan A. Burger. The network helps show where Jan A. Burger may publish in the future.

Co-authorship network of co-authors of Jan A. Burger

This figure shows the co-authorship network connecting the top 25 collaborators of Jan A. Burger. A scholar is included among the top collaborators of Jan A. Burger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan A. Burger. Jan A. Burger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and Cancer 2024 ·International Journal of Molecular Sciences ·Smith Rjh, Jan A. Burger, Rula Zain	1
2	Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study 2023 ·Cancers ·Jennifer A. Woyach, Paul M. Barr, Thomas J. Kipps, Jacqueline C. Barrientos, Inhye E. Ahn, Paolo Ghia, (unknown), Emily Hsu, (unknown), Jan A. Burger	10
3	Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity 2023 ·Cancer ·Max J. Gordon, Jade Jones, Binsah George, Christine B. Peterson, Jan A. Burger, Nitin Jain, Michael J. Keating, William G. Wierda, Jean‐Bernard Durand, Alessandra Ferrajoli	10
4	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study 2020 ·Clinical Cancer Research ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien	126
5	SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer 2019 ·Cancer Immunology Research ·(unknown), Ninghai Wang, Elisa ten Hacken, Shih‐Shih Chen, Atul K. Bhan, Abel Suárez‐Fueyo, Eri Katsuyama, George C. Tsokos, Nicholas Chiorazzi, Catherine J. Wu, Jan A. Burger, Roland W. Herzog, Pablo Engel, Cox Terhorst	42
6	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia 2019 ·Blood ·Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael Weiss, Susan O’Brien	64
7	Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS) 2019 ·Blood ·Veronica Guerra, Jan A. Burger, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Tapan M. Kadia, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Marina Konopleva, Courtney D. DiNardo	11
8	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2017 ·Clinical Cancer Research ·Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, (unknown), Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien	47
9	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies 2017 ·Blood ·Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, (unknown), Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz	183
10	Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex 2017 ·Molecular Cancer Research ·Uri Rozovski, David Harris, Ping Li, Zhiming Liu, Preetesh Jain, (unknown), Alessandra Ferrajoli, Jan A. Burger, Susan O’Brien, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating, Zeev Estrov	23
11	CLL progression after one cycle of FCR: Richter's transformation versus EBV‐associated lympho‐proliferation 2017 ·American Journal of Hematology ·Preetesh Jain, Jan A. Burger, Joseph D. Khoury	5
12	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics 2016 ·Clinical Cancer Research ·Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George A. Călin, Susan O’Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli	23
13	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Matthew D. Blunt, Stefan Koehrer, Rachel Dobson, Marta Larráyoz, (unknown), (unknown), (unknown), (unknown), Andrew Davies, Peter Johnson, Pamela B. Conley, Anjali Pandey, Jonathan C. Strefford, Freda K. Stevenson, Graham Packham, Francesco Forconi, Greg Coffey, Jan A. Burger, Andrew J. Steele	54
14	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop M. Kantarjian, Susan O’Brien, Jan A. Burger	45
15	Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells 2015 ·Molecular Cancer Research ·Uri Rozovski, Srđana Grgurević, Carlos Bueso-Ramos, David Harris, Ping Li, Zhiming Liu, Ji Yuan Wu, Preetesh Jain, William G. Wierda, Jan A. Burger, Susan O’Brien, Nitin Jain, Alessandra Ferrajoli, Michael J. Keating, Zeev Estrov	69
16	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia 2014 ·Clinical Cancer Research ·Marina Konopleva, Roland B. Walter, Stefan Faderl, Elias Jabbour, Zhihong Zeng, Gautam Borthakur, Xuelin Huang, Tapan M. Kadia, Peter P. Ruvolo, Jennie B. Feliu, Hongbo Lu, (unknown), Jan A. Burger, Michael Andreeff, Wenbin Liu, Keith Baggerly, Steven M. Kornblau, L. Austin Doyle, Elihu H. Estey, Hagop M. Kantarjian	70
17	Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia 2012 ·Journal of Clinical Oncology ·Xavier C. Badoux, Michael J. Keating, Sijin Wen, William G. Wierda, Susan O’Brien, Stefan Faderl, Rachel L. Sargent, Jan A. Burger, Alessandra Ferrajoli	113
18	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors 2011 ·Blood ·Mariela Sivina, Robert J. Kreitman, Amnon Peled, Farhad Ravandi, Jan A. Burger	10
19	Bone Marrow Stroma–Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor 2011 ·Cancer Research ·Taghi Manshouri, Zeev Estrov, Alfonso Quintás-Cardama, Jan A. Burger, Ying Zhang, (unknown), (unknown), David Harris, Chad J. Creighton, Hagop M. Kantarjian, Srđan Verstovšek	80
20	The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia breakdown → 2011 ·Blood ·Julia Hoellenriegel, Sarah Meadows, Mariela Sivina, William G. Wierda, Hagop M. Kantarjian, Michael J. Keating, Neill A. Giese, Susan O’Brien, Albert S. Yu, Langdon L. Miller, Brian J. Lannutti, Jan A. Burger	442

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact